|Table of Contents|

Exploration and evaluation of the radiotherapy plan for glioma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 18
Page:
3442-3446
Research Field:
Publishing date:

Info

Title:
Exploration and evaluation of the radiotherapy plan for glioma
Author(s):
WANG Peipei; LI Jinkai; LI Caihong; CAO Yuandong; CHANG Zhigang; GU Xiaohuan; DI Xiaoke; YANG Yan
Center of Radiation Oncology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Nanjing 210029,China.
Keywords:
glioma; VMAT; dose homogeneity; NTCP
PACS:
R730.55
DOI:
10.3969/j.issn.1672-4992.2023.18.020
Abstract:
Objective:To develop a radiotherapy plan to reduce the dose of normal brain by reducing the dose homogeneity of the tumor bed (GTVtb) for glioma,and evaluate the plans with dosimetric and radiobiological indicators.Methods:Twenty CT image-datasets of glioma patients treated by postoperative radiotherapy were selected.The prescribed dose of planning target volume (PTV) was 60 Gy/30 f(2 Gy/f),and two groups of plans were designed by volume-modulated arc therapy(VMAT),one group were conventional plan (the dose homogeneity of PTV was controlled between 95% and 107% of prescribed dose),the other group plans were reduced the homogeneity appropriately (the dose distribution homogeneity of GTVtb was controlled between 95% and 110% of prescribed dose),which were named Vhomo and Vinho respectively.The two groups of plans were evaluated under the condition that 95% of the volume of PTV met the prescribed dose.The dose differences of target and normal brain were evaluated by dosimetric parameters.The normal tissue complication probability (NTCP) were calculated by Matlab program based on equivalent uniform dose (EUD),which were used to evaluate the probability of radiation damage of normal brain.The efficiencies of the plan delivery were evaluated by the machine units (MUs) and the estimated delivery time calculated by the treatment planning system.Results:There were significant differences in D2%,D98% and Dmean of PTV between the two groups (P＜0.001).Compared to the Vhomo group,the D2% and Dmean of Vinho were higher,and D98% were lower.The mean conformity index (CI) of PTV were 0.88±0.03 in two groups with no significant differences.The mean values of HI were 0.08±0.01 and 0.10±0.02,respectively,with significant statistical differences(P=0).For the normal brain,the V50,V40,V20 and Dmean in Vinho group were all lower,showing statistically significant differences (P＜0.001),the NTCP of the two groups were statistically significant (5.21±3.30 vs 4.79±2.77) (P=0.048).Compared to the Vhomo,there was a significantly increase in MUs of the Vinho (P=0.001),but the delivery time was not prolonged,with no significant differences.Conclusion:The dose of normal brain can be decreased by reducing the limitation of the homogeneity of the target for the glioma,thus reducing the radioactive toxicity of patients,which can provide a reference for the planning design of glioma.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ OSTROM QT,CIOFFI G,WAITE K,et al.CBTRUS statistical report:Primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018［J］.Neuro Oncol,2021,23(12 Suppl 2):iii1-iii105.
［3］ WUJIANTO C,VELLAYAPPAN B,CHANG EL,et al.Radiotherapy to the brain:what are the consequences of this age-old treatment［J］.Ann Palliat Med,2021,10(1):936-952.
［4］ 田野,王绿化.放射治疗中正常组织损伤与防护［M］.北京：人民卫生出版社,2019:244-252. TIAN Y,WANG LH.Normal tissue injury in radiotherapy and its protection［M］.Beijing:People's Sanitary Publishing House,2019:244-252.
［5］ ICRU International Commission on Radiation Units and Measurements.Prescribing,recording,and reporting photon-beam intensity modulated radiation therapy(IMRT).ICRU report 83［J］.J ICRU,2010,10(1):1-106．
［6］ WANG JZ,LI XA.Impact of tumor repopulation on radiotherapy planning［J］.Int J Radiat Oncol Biol Phys,2005,61(1):220-227.
［7］ CHEN GP,AHUNBAY E,SCHULTZ C,et al.Development of an inverse optimization package to plan nonuniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images［J］.Med Phys,2007,34(4):1198-1205.
［8］ MIAO J,YAN H,TIAN Y,et al.Reducing dose to the lungs through loosing target dose homogeneity requirement for radiotherapy of non small cell lung cancer［J］.J Appl Clin Med Phys,2017,18(6):169-176.
［9］ NIEMIERKO A.Reporting and analyzing dose distribution:a concept of equivalent uniform dose［J］.Med Phys,1997,24(1):103-110.
［10］ NIEMIERKO A,GOITEIN M.Modeling of normal tissue response to radiation:the critical volume model［J］.Int J Radiat Oncol Biol Phys,1993,25(1):135-145.
［11］ EMAMI B,LYMAN J,BROWN A,et al.Tolerance of normal tissue to therapeutic irradiation［J］.Int J Radiat Oncol Biol Phys,1991,21(1):109-122.
［12］ GAY HA,NIEMIERKO A.A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy［J］.Phys Med,2007,23(3-4):115-125.
［13］ LAWRENCE YR,LI XA,EL NI,et al.Radiation dose-volume effects in the brain［J］.Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S20-S27.
［14］ SATHORNSUMETEE S,RICH JN,REARDON DA.Diagnosis and treatment of high-grade astrocytoma［J］.Neurol Clin,2007,25(4):1111-1139.
［15］ STUPP R,HEGI ME,MASON WP,et al.Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial［J］.Lancet Oncol,2009,10:459-466.
［16］ FLEISCHMANN DF,SCHON R,CORRADINI S,et al.Multifocal high-grade glioma radiotherapy safety and efficacy［J］.Radiat Oncol,2021,16(1):165.
［17］ LAPERRIERE N,ZURAW L,CAIRNCROSS G.Radiotherapy for newly diagnosed malignant glioma in adults:a systematic review［J］.Radiother Oncol,2002,64(3):259-273.
［18］ SMINIA P,MAYER R.External beam radiotherapy of recurrent glioma:radiation tolerance of the human brain［J］.Cancers(Basel),2012,4(2):379-399.
［19］ MINNITI G,NIYAZI M,ALONGI F,et al.Current status and recent advances in reirradiation of glioblastoma［J］.Radiat Oncol,2021,16(1):36.
［20］ ALLEN LI X,ALBER M,DEASY JO,et al.The use and QA of biologically related models for treatment planning:short report of the TG-166 of the therapy physics committee of the AAPM［J］.Med Phys,2012,39(3):1386-1409.
［21］ LUXTON G,KEALL PJ,KING CR.A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD)［J］.Phys Med Biol,2008,53(1):23-36.
［22］ JONES B,DALE RG.The evolution of practical radiobiological modelling［J］.Br J Radiol,2019,92(1093):20180097.
［23］ GAITO S,BURNET N,AZNAR M,et al.Normal tissue complication probability modelling for toxicity prediction and patient selection in proton beam therapy to the central nervous system:A literature review［J］.Clin Oncol (R Coll Radiol),2022,34(6):e225-e237.

Memo

Memo:
National Natural Science Foundation of China(No.82003228）；国家自然科学基金(编号：82003228)
Last Update: 1900-01-01